Swipha plans contract manufacture for multinationals – Launches five OTC products
(By Yusuff Moshood)
Swiss Pharma Nigeria Limited (Swipha) is fully set to produce essential medicines for non-governmental organisations (NGOs) and contract manufacture for multinational pharmaceutical companies, Mr Colin Cummings, chairman/CEO, Swipha, has said.
Mr Cummings made this disclosure while speaking with pressmen at a press briefing on the company’s GMP certification and the launch of five new over-the-counter (OTC) medicines. The events were held at Sheraton Hotel & Towers, Ikeja, Lagos, recently.
According to the Swipha’s helmsman, with the achievement of Swipha as the first pharmaceutical company in Nigeria and indeed the whole of the West African sub-region to be declared compliant with the standards of Good Manufacturing Practice (GMP), by the World Health Organisation (WHO), the company is bolstered to produce more quality products and compete with other reputable pharmaceutical companies globally.
Speaking further at the well-attended event, chaired by Prince Julius Adelusi-Adeluyi, the Swipha boss said that with this feat, the company has placed Nigeria on the global map of countries that can provide finished pharmaceutical products comparable in standards with other developed economies.
On what prompted the introduction of five new over-the-counter products by the company, Mr Cummings revealed that Swipha is always looking for new ways to meet its customers’ needs, providing solutions to their healthcare needs, and thereby helping to consistently improve the well-being of Nigerians.
The new products are SUPRA-FIT, SUPRA-KIDS, SUPRA-C, STAVLAN and GUAFENSIN.
Mr Cummings explained that SUPRA-FIT was formulated with the Nigerian diet and lifestyle in mind, adding that it is specifically for adults who need to supplement their daily vitamins and mineral intakes for optimal well-being. SUPRA-KIDS, he said, is a chewable multivitamin tablets for children aged 12 years and above.
SUPRA-C, according to him, is an anti-oxidant and an appetite stimulant for children, while STAVLAN is an adjunct in the treatment of liver disease. He further explained that GUAFENSIN is a non-drowsy cough expectorant for symptomatic relief of cough and cold.
The highpoint of the occasion was the official unveiling of the new products. The unveiling was done by the chairman of the event, assisted by other top-dignitaries that graced the memorable occasion.